12Oct 2023
FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with BRAF V600E Mutation

FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with BRAF V600E Mutation

Food and Drug Administration (FDA) approved encorafenib (Braftovi) in combination with binimetinib (Mektovi) for adult patients battling metastatic non-small cell lung cancer (NSCLC) harboring a BRAF V600E mutation. This decision comes after rigorous evaluation, with efficacy demonstrated in 98 patients involved in the PHAROS study. For treatment-naïve patients, the objective response rate (ORR) stood at 75%, and among previously treated patients, a 46% ORR was observed. The FDA also approved FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma) as companion diagnostics. Adverse reactions included common symptoms like fatigue, nausea, and diarrhea. Encorafenib and binimetinib are prescribed at specific daily doses for NSCLC patients with the BRAF V600E mutation.

  • #family health

Like

Save

Share